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Background: McCune Albright syndrome (MAS) is a rare disorder characterized by precocious puberty, café-au-lait
spots, and fibrous dysplasia. Its cause is an activating mutation in the GNAS gene, encoding a subunit of the
stimulatory G protein, Gsalpha (Gsα). The action of any mediator that signals via Gsα and cyclic AMP can be up
regulated in MAS. We had observed gastritis, gastroesophageal reflux, and anaphylaxis in McCune Albright patients.
Objective: As histamine is known to signal via histamine 1 (H1) and histamine 2 (H2) receptors, which couple with
stimulatory G proteins, we attempted to mechanistically link histamine responsiveness to the activating GNAS
mutation. We hypothesized that responsiveness to histamine skin testing would differ between MAS patients and
healthy controls.
Patients and methods: After obtaining informed consent, we performed a systematic review of histamine
responsiveness and allergic manifestations in 11 MAS patients and 11 sex-matched, Tanner-stage matched controls.
We performed skin prick testing, quantifying the orthogonal diameters of wheals and erythema. We also
quantitated G protein mRNA expression.
Results: The peak wheal and flare responses to histamine were significantly higher in MAS patients compared to
controls.
Conclusions: This study suggests that MAS patients may be at risk for exaggerated histamine responsiveness
compared to unaffected controls.
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McCune-Albright syndrome (MAS) is a rare, intriguing,
genetic disorder characterized by excessive activity of
multiple hormones and other mediators that signal
through cAMP. The original description by Fuller Al-
bright included the triad of precocious puberty, café-au-
lait skin spots, and polyostotic fibrous dysplasia [1]. The
causative mutation, identified in 1991, is a missense mu-
tation in the GNAS gene, which leads to constitutive ac-
tivation of the Gsα protein [2]. Mutations in the GNAS
gene occur after conception, and the individual survives
with mosaicism. As a result of this mosaicism, individ-
uals with MAS display a wide spectrum of clinical* Correspondence: jjacobson@cmh.edu
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reproduction in any medium, provided the orseverity and a wide range of endocrine manifestations.
Purely endocrine features described in MAS include
non-autoimmune hyperthyroidism, acromegaly, Cushing
syndrome, hyperprolactinemia, and hyperparathyroid-
ism. Bony problems include polyostotic fibrous dysplasia
[3-7]. Several non-endocrine features more recently at-
tributed to the molecular defect include platelet abnor-
malities, hepatobiliary disease, cardiac hypertrophy, and
sudden or premature death [2,8-11]. The ongoing recog-
nition of additional G protein-mediated signaling abnor-
malities in MAS may eventually lead to an increased
number of supportive diagnostic criteria to aid in accur-
ately diagnosing MAS.
We noted that a large number of our patients with
MAS displayed a wide variety of atopic manifestations
and hypersensitivities. Reactions ranged from asthma,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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anaphylaxis. In fact, over a period of three years, five
MAS patients experienced anaphylaxis. We speculated
that these observations were linked to the constitutive
activation of the stimulatory G protein, Gsα.
Our initial observations of severe reactions to foods
and inhalant allergies suggested classic IgE-mediated
problems. The IgE receptor cross-linking process is me-
diated by tyrosine kinases, and is therefore not G
protein-mediated. However, we note that G protein-
coupled receptors (GPCRs) and cyclic AMP modulate
numerous responses in neurological, immune, muscular,
and vascular systems that contribute to allergic pro-
cesses, asthma, and atopy. Classic examples of stimula-
tory G protein-coupled ligands that play crucial roles in
atopy are histamine and leukotrienes [12,13]. Stimula-
tory G protein-coupled ligands such as acetylcholine and
epinephrine play crucial roles in bronchoconstriction
[14,15]. Examples of stimulatory G protein-coupled li-
gands that play crucial roles in vasomotor function are
substance P and catecholamines [16,17].
We noted that two of our MAS patients suffered from
severe gastritis and gastroesophageal reflux. Such find-
ings are suggestive of H2 receptor activation. We specu-
lated that some of our observations of hypersensitivities
in MAS patients might be linked to exaggerated hista-
minic signaling augmented by the constitutive activity of
Gsα protein. However, of the four major histamine re-
ceptors, H1 through H4, only the H2 receptor is classic-
ally described as coupling to Gsα and cAMP [18-20].
Activation of this H2 receptor is traditionally not associ-
ated with allergy, but rather with gastric histaminic ac-
tivity. In contrast, the histamine 1 (H1) receptor, which
is traditionally associated with allergy and urticaria, is
coupled to a separate stimulatory G protein of the Gqα
pathway [20]. H3 and H4 receptors exert actions via in-
hibitory G proteins, which generally mediate cAMP in-
hibition [21,22].
Many lines of evidence suggest “cross talk” between
Gsα pathway (which traditionally signals via cAMP) and
Gq/11α pathway (which traditionally signals via inositol
phosphates) in the signaling of guanine nucleotide bind-
ing (G) protein coupled receptors (GPCRs), including
histamine receptors [13,20,23-27]. Constitutive co-
expression of a 5- hydroxytryptamine receptor with the
Gq/11 α coupled histamine 1 receptor results in increased
agonist-independent signaling, which can be augmented
by agonist activation of various other G protein coupled
receptors, including muscarinic and adenosine receptors
[28].
Previous studies have demonstrated that skin reactivity
to histamine testing varies with the menstrual cycle in
both healthy and atopic women, with heightened reactiv-
ity seen in midcyle, corresponding to peak estrogen andgonadotropin stimulation [29,30]. We have previously
reported that exposure to either estrogen or to
gonadotropin-releasing hormone (GnRH) stimulates
Gq/11α mRNA expression in immune cells in mice
[31,32]. Because patients with MAS exhibit post-receptor
activation of GnRH, LH, and FSH receptors, we specu-
lated that other G protein signaling pathways might be
up regulated in MAS.
Herein, we hypothesized that patients with MAS
would demonstrate evidence of increased H1 and/or H2
activity. We measured wheal and flare skin responses to
histamine compared to Tanner Stage matched, sex-
matched, unaffected controls. We also sought evidence
for increased allergic phenomena in MAS patients by
systematically reviewing their allergic histories. We
quantified expression of Gsα mRNA and Gqα mRNA
and protein in peripheral blood mononuclear cells
(PBMCs). We also sought a correlation between hista-
mine responsiveness and activation of the hypothalamic-
pituitary-gonadal axis, as measured by Tanner staging.
Patients and methods
Study design
This is a single-center, prospective, nonrandomized
study comparing patients with the clinical diagnosis of
MAS to Tanner stage-matched, sex-matched healthy
controls. The study and all procedures were approved by
the Institutional Review Board and performed in compli-
ance with the World Medical Association Declaration of
Helsinki regarding the ethical conduct of research. All
participants were evaluated over a 3 year period begin-
ning in August of 2004. Two separate consent forms
were utilized for G protein measurement, Tanner sta-
ging, allergic histories, IgE measurements, and skin test-
ing. Histories of allergic histories and medical therapies
for allergies were obtained retrospectively. Menstrual
histories were taken in female participants. Pubertal de-
velopment was assessed by Tanner stage of pubic hair
and breast development (girls) and testicular volume
(boys) [33].
MAS participants
We identified 12 MAS patients who were regularly
followed in our endocrinology clinic. The diagnosis was
diagnosed based on clinical criteria. Patients were re-
quired to exhibit at least two major features of MAS
(precocious puberty, polyostotic fibrous dysplasia, and
café-au-lait spots). All patients underwent endocrine
evaluations including thyroid function testing at least
annually. Only one female patient with MAS exhibited
regular menstrual cycles. After obtaining informed con-
sent, we obtained information about adverse drug and
food reactions retrospectively from the medical record
charts. One out of the 12 patients was unable to
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This patient had a history of anaphylaxis necessitating
epinephrine administration after receiving radiographic
contrast. The clinical characteristics of the 11 participat-
ing patients with MAS are shown in Table 1.
Control participants
Healthy control children with no increased risk for aller-
gies were recruited by an institutional electronic adver-
tisement. An allergy questionnaire was administered to
all patients and controls. Allergic manifestations in con-
trols were similar to that seen in the general population.
One out of eleven (9%) controls reported seasonal rhin-
itis. No other allergic phenomena were reported in con-
trol participants.
Controls were Tanner Stage-matched to MAS patients.
Because MAS patients exhibited precocious puberty, we
matched patients and controls by Tanner Stage rather than
by age. In order to match by age, we would have had to use

















1 17 M 5 Yes Yes Yes
2 15 F 5 No Yes Yes
3 12 F 3 Yes Yes Yes
4 13 F 3 Yes Yes Yes
5 13 F 3 Yes Yes Yes
6 10 F 1 Yes Yes No
7 8 F 3 Yes Yes Yes
8 17 F 5 Yes Yes Yes
9 7 F 2 No Yes Yes
10 7 F 2 No Yes Yes
11 16 M 5 Yes Yes NoEleven Tanner stage-matched, sex-matched control pa-
tients underwent skin testing. Two of these control par-
ticipants had undergone Tanner staging for clinical care
purposes. The Tanner stage(s) of these individuals was
therefore not recorded in the research record. Two female
control participants had already achieved menstrual regu-
larity. A second set of 11 sex-matched, Tanner stage-
matched control participants did not undergo skin testing,
but were recruited specifically for G protein measurement,
in order to increase the sample size of controls.
Power analysis
Pilot data in mice demonstrated that early exposure to
estradiol leads to a three-fold increase in expression of
mRNA for stimulatory G proteins in various tissues. As
MAS patients exhibit early activation of the HPG axis,
we speculated that similar differences might be seen in
humans. A power analysis revealed that an n of 8 would
yield an 80% power to detect similar differences in G














Yes 4 107 21 anaphylaxis (latex), drug
allergies (morphine,













No 3 98 7 anaphylaxis (penicillin)




Yes 3 70 12 multiple drug allergies
(methimazole,
propylthiouracil)
No 3 112 10 drug allergy (letrozole)
Other sensitivities (gluten,
surgical tape), chronic urticaria
No 3 98 14 asthma, latex allergy
No 2 75 18 atopic dermatitis, seasonal
rhinitis, chronic urticaria
No 2 92 14 asthma, seasonal rhinitis
No 2 135 17 none
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ferences in G protein mRNA expression.
Skin testing
If patients had received antihistamines or glucocorti-
coids in the two weeks prior to IRB consent, they were
excluded and consented when they were no longer re-
quiring these medications. Blood was drawn for IgE
measurement. Participants then underwent standard al-
lergy testing using the commercially available Greer Skin
testing system as a prick test device (Greer Labs, Lenoir,
N.C.). Histamine (Hollister-Stier Laboratories, Spokane,
WA) was used at a concentration of 6 mg/ml. Codeine
(20 mg/ml; Hospira, Inc., Lake Forest, IL) was used as a
control whose actions are mediated by IgE independent
histamine release [34]. It signals via both stimulatory
and inhibitory G proteins [35]. Normal saline was also
used as a negative control. Tests were spaced at least
3 cm apart to avoid difficulty with interpretation. Two
standard sites were used for skin testing for all partici-
pants, the back and the arm. When cutaneous café-au-
lait spots were present on standard sites on the back or
arm (n = 4), the solutions were also applied to the
contralateral unaffected skin site. Data from the un-
affected skin sites only were used in comparisons be-
tween MAS patients and controls. All testing was
performed by a single trained allergy nurse. Wheal and
flare responses were measured at 7 and 20 minutes after
the skin tests were administered. The wheal and flare re-
sponses were outlined in ink, and the image transferred
to hypoallergenic transparent tape to create a permanent
record. Tape was placed in a permanent record book for
measurement. Thus, measurement was performed with
blindness to the skin pigmentation. The longest diameter
of erythema was measured. A line was drawn perpen-
dicular to the longest diameter of erythema (the orthog-
onal diameter) and also measured. These two lengths
were arithmetically summed, according to a standard,
published protocol, as delineated in Figure 1 [36]. The




Figure 1 Diagram depicting the method of measurement of
the sums of wheal and flare (Σ of flare) responses to histamine
skin testing.response to histamine, which was, in all cases, smaller
than the erythema measurement. The intra-individual
coefficient of variation of this histamine skin prick test-
ing is reported to be 20% [37]. In the current study the
coefficient of variation in flare response to histamine
was 32% in controls. Peak reactions, irrespective of ana-
tomical location, and site-specific wheal and flare re-
sponses were compared between MAS patients and
controls. Epinephrine pens were available at the bedside
during skin testing.
Genetic testing
The three study subjects who displayed anaphylactic re-
actions underwent genetic testing for mutations in
GNAS in peripheral blood. Mutational analysis of the
Arg 201 locus of GNAS was performed using site-
specific polymerase chain reaction (PCR), restriction di-
gestion and DNA sequencing.
PBMC isolation
PBMCs were isolated from heparinized blood using
Histopaque 1077 (Sigma-Aldrich, St. Louis, MO). Cells
were pelleted, and resuspended in Buffer RLT Plus from
the RNeasy® Mini Plus Kit (QIAgen, Valencia, CA) and
stored at -80°C until further processing.
RNA isolation and quantitation
Samples were thawed, vortexed, and placed in
QIAshredder columns and processed according to the
manufacturer’s directions. RNA was examined by spec-
trophotometry and quantitated using the Ribogreen
assay (Invitrogen, Carlsbad, CA). Ribogreen reagent was
added to samples and standards, and samples were read
on a Bio-Tek FL 800 fluorescent plate reader. RNA was
diluted in nuclease-free water to a final concentration of
150 ng/ml cDNA. RNA quality was assessed by spectro-
photometry and by the cycle number for the housekeep-
ing gene, GAPDH.
Reverse transcription and one-step real time PCR
DNA was digested using DNase 1, and residual DNase
activity was quenched with EDTA. Reverse transcription
was then performed using the SuperScript II Reverse
Transcription Kit (Invitrogen, Carlsbad, CA) according
to the manufacturer’s instructions. One-step real-time
RT-PCR was performed using the SYBR Green PCR kit
(Bio-Rad, Hercules, CA). G protein sequences were
obtained from the Gene Bank database and the following
primers were constructed Using the GenBank sequence
for GNAS NM_ 000516: Gsα sense: 5′-TCT ACC GGG
CCA CGC ACC GC-3′; Gsα antisense: 5′-GCA GGA
TCC TCA TCT GCT TC-3′. We utilized the human
GNAQ sequence NM_002072 to create the following
primers: Gqα sense: 5′-GAT GTT CGT GGA CCT GAA
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GTC CT-3′. BLAST searches were performed using the
National Center for Biotechnology Information’s BLAST
WWW Server. Commercially available primers were
used for the housekeeping gene, GAPDH (Clontech,
Mountain View, CA). The following parameters were
used for the RT-PCR program for all genes: 95°C 3 min;
35 cycles of 95°C 20 sec, 56°C 20 sec, 72°C for 20 sec;
95°C 1 min; and 55°C 7 min. Data were calculated as the
delta Ct ratio of the gene of interest compared to the
delta Ct of the housekeeping gene (GAPDH). That ratio
was also normalized as a percent of an internal standard
control sample, prepared from a pool of PBMCs from
healthy adult males and females.
Protein quantitation
Protein concentrations were determined by the Bradford
method utilizing a Coomassie protein assay kit from
Pierce Biotechnology (Rockland, IL). A standard curve
using bovine serum albumin was established from 0 to
2000 μg/ml. Sample (5 μl) was added to 96 well plates in
duplicate. Coomassie reagent (250 μl) was added to each
well and incubated for 10 minutes at RT. The absorb-
ance was measured at 595 nm on a Power WaveX plate
reader (Bio-Tek, Winooksi, VT).
Immunoblot analysis for membrane-associated proteins
Total membrane protein (200 μg per well) was
electrophoresed in 12% Tris–HCl gels and transferred to
nitrocellulose membranes (Biorad, Hercules, CA) by
electroblotting. Membranes were blocked in Tris-
buffered saline with .1% Tween-20 (TBST) and 5% non
fat dry milk, then incubated overnight with affinity-
purified rabbit polyclonal IgG antibodies specific to each
G protein (Santa Cruz Biotechnology, Santa Cruz, CA).
The Gqα antibody does not cross- react with the related
G protein subunit, G11α. Membranes were incubated for
1 h in TBST with horseradish peroxidase conjugated 2°
antibodies (Jackson Immunoresearch, West Grove, PA).
Bands were visualized by chemiluminescence via western
blot luminal reagent (Santa Cruz Biotechnology, Santa
Cruz, CA) by exposure to Classic BX autoradiography
film (MidSci, St. Louis, MO). The membranes were then
stripped with western blot stripping buffer (Fisher Scien-
tific, Hanover Park, IL) for 30 min at 37°C and re-
probed for actin protein as an internal control, using a
monoclonal primary antibody (MP Biomedicals, Santa
Ana, CA). Bands were quantitated using densitometry
and ImageQuant 5.2 software (Molecular Dynamics,
Foster City, CA).
Sequencing
Gsα and Gqα PCR fragments were treated with ExoSAP-
IT (USB, Cleveland, OH) and subsequently sequencedusing BigDye terminator v3.1 cycle sequencing chemis-
try and a 3730 capillary DNA analyzer (Applied
Biosystems, Foster City, CA).
Statistics
Differences in skin testing results between groups were
assessed using 95% confidence intervals. G protein
mRNA expression and IgE levels were compared by
Wilcoxon rank sum tests. Because data were not nor-
mally distributed, Spearman correlation coefficients were
determined comparing Tanner stage and peak histamine
responses and between G protein mRNA and protein
measurements.
Results
Atopic manifestations and hypersensitivities
Retrospective analysis revealed that ten out of 11
(90.9%) patients with MAS in this study displayed atopy
and hypersensitivities encompassing a wide variety of re-
actions (Table 1). Allergic phenomena suggestive of H1
receptor activation included seasonal rhinitis, eczema,
asthma, food allergies, drug reactions, latex allergies,
and anaphylaxis. Activation of the H2 receptor was sug-
gested by chronic gastritis, H. pylori negative ulcers, and
gastroesophageal reflux noted in two patients. Type IV
reactions, including severe bullous reactions to surgical
tape occurred in two individuals. Anaphylaxis necessitat-
ing epinephrine administration had occurred in four of
the 11 patients in the current study. Two of these pa-
tients experienced anaphylaxis after food ingestions, one
after skin contact with latex, and one after receiving
penicillin.
Flare responses to histamine
Patients with MAS displayed significantly more vigorous
flare responses to histamine when comparing the same
anatomical site to that of controls. The sum of the skin
flare response to histamine on the back was 92.7 ±
20.0 mm in MAS patients compared to 66.1 ± 12.4 mm
in controls (mean ± S.D.) (95% confidence interval (CI)
11.8 to 41.4; p = 0.0013: Figure 2).
Similar flare responses were seen using the arm, al-
though more variability was seen: 92.4 ± 30.2 mm in
MAS patients compared to 68.3 ± 25.7 mm in controls
(95% CI −0.8 to 49.0; p = 0.057).
The peak flare response to histamine irrespective of
anatomical location was also significantly higher in pa-
tients with MAS compared to controls [104.4 ± 24.4 mm
in MAS patients compared to 76.4 ± 12.9 mm in con-
trols (95% CI 10.6 to 45.4; p = 0.003)].
Wheal responses to histamine
Patients with MAS also displayed significantly more vig-

















Controls      MAS
*
Figure 2 Vertical dot plot depicting the sum of flare (Σ of flare)
responses to histamine skin testing on the back in control
participants and in patients with MAS. * A significantly higher
histamine response is seen in MAS patients compared to controls
(n = 11 per group; p = 0.004).
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wheal response to histamine on the back was 12.8 ±
3.7 mm in MAS patients compared to 9.3 ± 3.1 mm in
controls (95% CI 0.46 to 6.54; p = 0.026; Figure 3).
No statistically significant differences in wheal re-
sponses in the arm were seen: 13.7 ± 3.8 mm in MAS





















Figure 3 Vertical dot plot depicting the sum of wheal (Σ of
wheal) responses to histamine skin testing on the back in
control participants and in patients with MAS. Each group
included one patient whose wheal measurement was not recorded.
*A significantly higher histamine response is seen in MAS patients
compared to controls (p = 0.01).−3.50 to 4.70; p = 0.76). The differences in the peak
wheal response to histamine irrespective of anatomical
location between patients and controls also did not
reach statistical significance 14.5 ± 4.1 mm in MAS pa-
tients compared to 13.6 ± 5.4 mm in controls (95% CI
−3.364 to 5.164; p = 0.66).Responses to codeine
No differences were seen in wheal or flare responses to
codeine. The sum of the skin flare response to codeine
on the back was 37.8 ± 39.3 mm in MAS patients com-
pared to 24.7 ± 26.3 mm in controls (95% CI −16.6 to
42.8;p = 0.36). The sum of the skin wheal response to co-
deine on the back was 8.8 ± 5.9 mm in MAS patients
compared to 6.3 ± 2.7 mm in controls (95% CI −1.7 to
6.7; p = 0.22).G protein mRNA expression
Sufficient quantities and quality of mRNA for PCR ana-
lysis were obtained from 9 to11 participants per group.
No statistically significant differences between Gsα
mRNA levels were seen in patients versus controls. In
contrast, MAS patients displayed significantly elevated
median levels of Gqα mRNA compared to controls
(Figure 4; n = 9-11 per group; p =0.039). This difference
was confirmed using the larger data which included two
sex-matched, Tanner stage matched control participants
for every patient with MAS. The median Gqα mRNA level






























Gαs mRNA        Gαq mRNA
Controls
MAS
Figure 4 Whisker plot of Gαs mRNA and Gαq mRNA in controls
versus MAS participants. Sufficient quantities and quality of mRNA
were available on 9 to 11 participants per group. Although no
differences are seen in Gαs mRNA, * Gαq mRNA is significantly
higher in MAS patients compared to controls (p = 0.039). The solid
lines within the boxes represent median values.
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Sufficient quantities of protein for immunoblot analysis
were obtained from nine participants per group. No sta-
tistically significant differences between Gsα or Gqα pro-
tein levels were seen in patients versus controls. A direct
positive correlation was seen between Gqα mRNA and
Gqα proteins, but in control participants only (rho =
0.61; p = 0.03; data not shown).
Effect of café-au-lait spots
No significant differences in wheal or flare responses to
histamine, codeine, or saline were observed between the
affected skin lesions to the contralateral unaffected skin
site.
Effect of severity of disease
A regression analysis was performed comparing the
number of traditional manifestations of MAS and peak
flare in response to histamine. No correlation was seen,
Spearman (r) = − 0.22; p = 0.477.
Effect of puberty
A regression analysis comparing Tanner stage to the
maximum histamine flare response irrespective of ana-
tomical site showed significant direct positive correla-
tions in both patients with MAS and in control
participants. The Spearman correlation coefficient (r) for
MAS patients was 0.67; p = 0.02. The Spearman r for
control participants was 0.64; p = 0.03; Figure 5.
IgE levels
The mean IgE level in MAS patients was 653.1 ± 1195.9
kU/L and 81.0 ± 100.7 kU/L in controls. This difference
did not reach statistical significance (p = 0.149).Tanner Stage
























Figure 5 Regression analysis demonstrating a direct, positive
correlation between Tanner stage and the maximum sum of
flare responses to histamine skin testing irrespective of
anatomical site in patients with MAS (n = 11; Spearman r = 0.67;
p = 0.02) and in healthy control participants (n = 9; Spearman
r =0.64; p = 0.03).Genetic testing
An Arg 201 mutation was detected in exon 8 in one of
the three participants who underwent genetic testing
after experiencing anaphylaxis. This is patient #1, the
most severely affected patient.
Discussion
We have identified a high rate of allergic phenomena
and hypersensitivities in patients with MAS compared to
controls. In the current study, ninety-one percent of pa-
tients exhibited allergic phenomena ranging in severity
from medication allergies to anaphylaxis. This is the first
such report of atopy in McCune Albright syndrome in
the medical literature. These observations ranged from
classic IgE mediated phenomena to classic Type IV
hypersensitivity reactions such as contact dermatitis.
The wide range of sensitivities seen may result from the
fact that numerous neurotransmitters, chemokines, cyto-
kines, leukotrienes, and vasoactive peptides exert their
actions via stimulatory G proteins, and predominantly
via Gsα.
We have also observed a heightened wheal and flare
response to histamine skin testing in MAS patients. This
observation may be considered surprising, as the mo-
lecular defect in MAS is a constitutive activation of Gsα.
Of all the histamine receptors, only H2 receptors signal
via Gsα. Although H2 receptors are important in gastric
acid secretion, they are thought to play a minor role in
allergy and in urticaria. In those conditions, H1 recep-
tors, which signal via Gqα, are thought to play predom-
inant roles.
We did not observe a statistical increase in wheal and
flare responsiveness to codeine in MAS patients com-
pared to controls. If the heightened wheal and flare re-
sponses could be attributed solely to effects of
histamine, one might have expected similar results with
codeine as with histamine, as codeine induces histamine
release by mast cells [34]. The differences in responsive-
ness to codeine and histamine could relate to the fact
that codeine exerts its actions via an IgE independent
mechanism and via classic opioid receptors, which signal
via Gqα as well as via inhibitory G proteins [35]. Codeine
has been shown to exert additional actions in mast cells,
including cytokine and chemokine release [35].
It is possible that the exaggerated histamine responses
observed herein may have been amplified by gonadal
hormones. The hypothalamic pituitary gonadal axis is
known to be activated in female patients with MAS with
sexual precocity. In support of this hypothesis, previous
studies show a variation in histamine skin testing re-
sponses during the menstrual cycle and a positive correl-
ation between serum estradiol and LH levels in females
[29,30]. We did not measure gonadotropins of estradiol
in our population, as these are dramatically altered by
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tients exhibited regular menstrual cycles. We used Tan-
ner staging as a surrogate for chronic hormone
exposure. Although our numbers are small, we have
demonstrated statistically significant positive correla-
tions between histamine responses and Tanner stage
both in our MAS population and in healthy control
participants.
We speculate that the aberrant activation of the hypo-
thalamic pituitary gonadal axis in MAS may contribute
to the activation of Gqα and the H1 receptor pathways.
In fact, we have previously demonstrated that exposure
to estradiol or GnRH leads to a transcriptional
upregulation of Gq/11α [32]. Herein, we observed an
upregulation in Gqα mRNA expression in MAS partici-
pants compared to controls and confirmed these finding
in a larger sample size. It is perhaps not surprising that
we did not observe a transcriptional upregulation in Gsα
in MAS patients. This may relate to the mosaicism in
this condition. In the presence of an activating mutation
of the GNAS gene in MAS, further transcriptional
upregulation of GNAS would not seem to be adaptive.
The constitutive activation of a stimulatory G protein
in the clinical condition of MAS may offer important in-
sights into mechanisms in histamine signaling. Constitu-
tive activity of one GPCR in the absence of ligand
binding may have important implications for histamine
“cross talk.” It is interesting to note that antihistamines
are actually inverse agonists, meaning that they can re-
duce histamine receptor constitutive activity in the ab-
sence of binding of any histaminic ligand. Our results
support the possibility that the constitutive activation of
one G protein coupled histamine receptor, namely Gsα,
may offer a permissive effect on Gqα activity. Numerous
in vitro studies examining other agonists that signal
through GPCRs have shown that expression of constitu-
tively active stimulatory G protein coupled receptors al-
lows for enhanced signaling of other co-expressed G
protein receptors [23-25]. In fact, synergism has been
demonstrated between H1 and H2 receptors, with cross
talk between the Gqα/PKC and the Gsα/PKA pathways
[13,20,27].
One proposed mechanism for these observations is
that both H1 and H2 agonists compete for clearance by
the same cytochrome P450 isoenzyme [38]. This mech-
anism could not explain the numerous reports of
in vitro cross talk between H1 and H2 receptors, how-
ever [13,27]. Again, our data are consistent with the con-
cept that the constitutive activation of Gsα may offer a
permissive effect on Gqα -coupled receptors.
Human clinical studies also support the concept of
“cross talk” between H1 and H2 action in dermatologic
manifestations: H2 blockers have been noted to be clin-
ically beneficial in the management of chronic urticariaand dermographism [26,39,40]. A recent meta-analysis
showed that a combination of ranitidine with diphen-
hydramine was slightly more effective at improving the
resolution of urticaria than diphenhydramine adminis-
tered alone [41]. However, the authors concluded that
the review did not allow confident decision-making
about the use of H2 receptor antagonists for urticaria
[41].
A limitation of the study was that it is difficult to posi-
tively confirm the diagnosis in MAS. Genetic testing by
PCR methods currently is available, but it detects the
mutation in peripheral blood in only an estimated 40%
of individuals because of the mosaicism of this condi-
tion. The detection rate can be increased significantly
when cellular bony tissue is available. The diagnosis of
McCune Albright syndrome remains a clinical one,
which necessitates the presence of at least two features
of the classic triad [11].
Another limitation of the study was that the study
numbers are small. If increased atopy or excessive hista-
mine responsiveness can be confirmed in a larger group
of patients, especially in patients with molecularly con-
firmed MAS, inclusion of allergic phenomena among
the supporting diagnostic criteria of MAS may be
warranted. Additional supportive diagnostic criteria
would be extremely clinically useful in the management
of patients with MAS. A high frequency of formes frustes
variants exists in this condition. For example, patients
with isolated monostotic and polyostotic fibrous dyspla-
sia have been shown to display activating mutations in
GNAS without the full spectrum of McCune Albright
syndrome [42-44]. Variable tissue expression, mosaicism,
and non-confirmatory genetic testing in this condition
all lead to underdiagnosis of MAS.
Another limitation of the study was the lack of a
dose–response curve. If MAS patients indeed possess
exaggerated wheal and flare responses to both histamine
and to saline compared to controls, as our data suggest,
perhaps the differences between MAS patients and con-
trols could have been further amplified at much lower
doses of histamine.
The current study raises the possibility that in vivo or
in vitro testing for heightened responsiveness to other G
protein-linked endocrine or non-endocrine mediators
could eventually lead to improved clinical diagnostic
testing for MAS.
The current findings, which have implications in both
the diagnosis and management of MAS, indicate a need
for confirmatory studies in a larger series of patients
with genetically confirmed MAS.Competing interests
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